Location History:
- Le Kremlin-Bicêtre, FR (2020)
- Le Kremlin-Bicetre, FR (2020 - 2023)
- Kremlin-Bicetre, FR (2020 - 2023)
Company Filing History:
5 out of 1,745 
3 out of 99 
2 out of 81 
Years Active: 2020-2023
Title: The Innovative Contributions of Petrus Lenting
Introduction
Petrus Lenting, an accomplished inventor from Le Kremlin-Bicetre, France, is renowned for his innovative advancements in the field of biotechnology. With a total of six patents to his name, Lenting has significantly contributed to the development of therapies that address bleeding disorders.
Latest Patents
Among his latest inventions is a pioneering monoclonal antibody designed for the prevention and treatment of bleeding episodes. This isolated monoclonal antibody specifically binds to the D4 domain of von Willebrand Factor (VWF) and competes with ADAMTS13, partially inhibiting the degradation of VWF. It holds potential for treating patients with aortic stenosis and those utilizing ventricular assist devices (VAD).
Additionally, Lenting has developed isolated single-domain antibodies targeting the VWF D'D3 domain. These antibodies are combined with blood clotting factors to offer therapeutic options for managing hemostatic disorders. His inventive approach includes methods to extend the half-life of therapeutic polypeptides by integrating these single-domain antibodies.
Career Highlights
Throughout his illustrious career, Petrus Lenting has made significant contributions while working at prestigious organizations, including the Institut National de la Santé et de la Recherche Médicale and the Université Paris-Sud. His dedication to biomedical research has led him to be recognized in the scientific community.
Collaborations
Lenting’s journey as an inventor has seen fruitful collaborations with esteemed colleagues such as Olivier Christophe and Cécile Denis. These partnerships have enriched his research endeavors and complemented his innovative spirit.
Conclusion
Petrus Lenting's work exemplifies the essence of innovation in the medical field. His contributions are crucial in advancing the understanding and treatment of bleeding disorders, showcasing the transformative power of invention in improving patient outcomes. His ongoing research promises to pave the way for new therapeutic possibilities, firmly establishing his legacy in the realm of biotechnology.